The FDA granted accelerated approval to Inovio’s plasmid DNA immunotherapy INO-3107 for adults with recurrent respiratory papillomatosis after a Phase I/II trial in 32 patients showed 72% achieved a 50%–100% reduction in surgeries at 1 year. In a 2-year retrospective follow-up of 28 of those patients, 86% had at least a 50% reduction in surgeries and 50% required no surgeries at all.

Why It Matters To Oncology

• INO-3107, to be marketed as Voceryq, is a recombinant plasmid DNA-based immunotherapy designed to generate an antigen-specific T-cell response against HPV-6 and HPV-11, the viral drivers of recurrent respiratory papillomatosis.

• For clinicians in oncology and drug discovery, the approval underscores continued regulatory openness to immune-based, genetically encoded therapies beyond cancer, especially in HPV-driven disease biology.

• RRP is not a malignancy, but it shares translational themes familiar to oncology: viral antigens, immune activation, repeat procedures as a disease burden endpoint, and platform competition across modalities.

• The approval also adds competitive context to the HPV-6/11 space, where Precigen’s Papzimeos won full FDA approval last year using an adenoviral vector-based approach.

The Financials

• Inovio now has an FDA-cleared commercial product in a rare disease setting, potentially validating its broader DNA medicines platform.

• Accelerated approval can materially improve partnering and platform credibility, particularly for developers working on encoded immunotherapies and antigen-specific approaches.

• The RRP market is specialized, but reduced need for repeat surgeries could support a compelling value proposition if real-world durability holds.

What They're Saying

• The FDA based the decision on a single-arm Phase I/II study in 32 adults with RRP, with surgery reduction serving as the headline clinical outcome.

• At 1 year, 7 of 26 patients with at least three baseline surgeries (27%) required no surgeries after treatment.

• Common adverse events were injection site reactions, headache, fatigue, hypertension, nausea, and dizziness.

• The product consists of 2 plasmids: one encoding HPV target proteins and another encoding IL-12 to boost immune response.

What's Next

• Clinicians will watch for confirmatory evidence, durability, and uptake relative to existing RRP options, including other immune-based therapies.

• Drug discovery teams should track whether this approval strengthens interest in plasmid DNA delivery, cytokine-augmented constructs, and HPV-directed immunotherapy design.

• Real-world use will help clarify which patients benefit most, how durable surgery reduction is, and whether safety remains manageable outside trial settings.

Reference: Inovio's immunotherapy is second to win an FDA nod for HPV-driven respiratory growths